BioVie Inc. (BIVI)
| Market Cap | 11.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.48M |
| Shares Out | 7.54M |
| EPS (ttm) | -4.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,504 |
| Open | 1.570 |
| Previous Close | 1.590 |
| Day's Range | 1.550 - 1.688 |
| 52-Week Range | 1.060 - 13.200 |
| Beta | 0.56 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About BIVI
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly... [Read more]
Financial Performance
Financial StatementsNews
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
The presentation highlighted imminent clinical data readouts for bezisterim in Parkinson's and long COVID, both representing multi-billion dollar U.S. market opportunities. The company is advancing a spin-off for its liver disease asset and is considered undervalued with strong insider ownership.
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Transcript: Status update
Bezisterim is advancing in phase II trials for Parkinson's and long COVID, with key data readouts expected in Q2 and late summer 2024. BIV201 for ascites is preparing for phase III after strong phase II results. Strategic focus is on Parkinson's, with long COVID as a potential priority if results and FDA guidance are favorable.
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your right...
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
BioVie Transcript: AGM 2025
The meeting established a quorum, elected six directors for a one-year term, ratified EisnerAmper, LLP as auditor for 2026, and approved an amendment to the 2019 Omnibus Equity Incentive Plan. All proposals passed with strong majority support.
BioVie Transcript: Investor Update
Multiple clinical trials are progressing, with key data readouts for Parkinson's, Long COVID, and ascites expected by mid-2026. Lead drug bezisterim targets TNF-alpha and shows promise in neurodegenerative and inflammatory conditions, while financial runway extends through 2026.
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurode...
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue ...
BioVie Inc. Announces Pricing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debi...
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA...
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission Seasoned leaders bring deep expertise in neuroscience drug d...
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes p...
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurolog...
BioVie Transcript: AGM 2025
A quorum was established with nearly all shares represented. Shareholders approved both the reverse stock split proposal and the adjournment authority, with over 79% and 81% support, respectively.
BioVie Transcript: Status Update
Bezisterim, an oral anti-inflammatory targeting the ERK/NF-kappa B pathway, is being evaluated in the Sunrise PD phase II trial for early Parkinson's. The study uses both home-based and traditional assessments, aiming to demonstrate disease modification and improved motor and non-motor symptoms.
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurolog...
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurol...
Bronstein, Gewirtz & Grossman, LLC Encourages BioVie Inc. (BIVI) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI...
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioVie Inc. (BIVI) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior t...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioVie Inc. (BIVI) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior t...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). In...